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Coronary artery aneurysms (CAAs) are uncommon and describe a localized dilatation of 
a coronary artery segment more than 1.5-fold compared with adjacent normal segments. 
The incidence of CAAs varies from 0.3 to 5.3%. Ever since the dawn of the interventional 
era, CAAs have been increasingly diagnosed on coronary angiography. Causative factors 
include atherosclerosis, Takayasu arteritis, congenital disorders, Kawasaki disease (KD), 
and percutaneous coronary intervention. The natural history of CAAs remains unclear; 
however, several recent studies have postulated the underlying molecular mechanisms 
of CAAs, and genome-wide association studies have revealed several genetic predispo-
sitions to CAA. Controversies persist regarding the management of CAAs, and emerging 
findings support the importance of an early diagnosis in patients predisposed to CAAs, 
such as in children with KD. This review aims to summarize the present knowledge of 
CAAs and collate the recent advances regarding the epidemiology, etiology, pathophys-
iology, diagnosis, and treatment of this disease.
Keywords: coronary artery aneursym, atherosclerosis, coronary artery disease, coronary stent, coronary artery 
ectasia, coronary aneurysm
iNTRODUCTiON
Coronary artery aneurysms (CAAs) are uncommon and describe a localized dilatation of a coronary 
artery segment more than 1.5-fold the normal size of adjacent normal segments (1). Several large 
angiographic series have contributed to the understanding of CAAs. This review aims to summarize 
the present knowledge on CAAs.
DeFiNiTiON AND CLASSiFiCATiON OF CAAs
Coronary artery aneurysms describe local dilatations in the coronary artery that are 1.5-fold greater 
than normal adjacent segments. Coronary artery ectasias, on the other hand, appear as diffuse 
arterial dilatations, where the length of the dilated segment is found to be more than 50% of the 
diameter (1). Depending on the integrity of the vessel wall, aneurysms can be classified as true or 
false aneurysms (pseudoaneurysms). Pseudoaneurysms are dilatations of the vessel, with single or 
double layers of the vessel wall (rather than the normal three-layered structure), because of disrup-
tion of the media and external elastic membrane. They are usually caused by blunt chest trauma or 
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coronary intervention. In contrast, a true arterial aneurysm is a 
fusiform or saccular dilatation of the artery, involving the three 
layers of the vessel’s tunica. Some authors describe dilatations that 
exceed 4 cm in diameter as giant coronary aneurysms (2).
ePiDeMiOLOGY
The overall incidence of CAAs ranges from 0.3 to 5.3%; a pooled 
analysis states a mean incidence of 1.65% (1–8). The incidence of 
giant CAAs is as low as 0.02%, while the incidence of those associ-
ated with congenital artery fistulae are 5.9% (3). Nevertheless, the 
true burden of CAAs and ectasia may be currently underestimated. 
The use of non-invasive technology such as computed tomography 
(CT) and magnetic resonance (MR) coronary angiography may 
increase the recognition of this entity (5). A wide variation exists in 
the occurrence of CAAs, which could mean that the reported inci-
dences may not accurately represent the wider population. This 
could be explained by many factors such as the varied angiographic 
criteria used to define CAAs (2–5) or the differing definitions of 
CAAs used by various institutions (9). For example, some studies 
include both aneurysmal coronary disease and ectasia in their CAA 
incidence calculations, while others do not (9, 10). Moreover, each 
angiographic diagnosis of a CAA is operator dependent; therefore, 
any interobserver variability may contribute to the differences 
in the incidence data reported (9). Likewise, the geographical 
variation in these studies highlights important genetic and envi-
ronmental influences that affect the incidence of CAAs, of which 
the former shall be discussed later. The CAA incidence has been 
shown to be lower in Asia than in North America and Europe. In 
a study on 302 patients with Kawasaki disease (KD), the incidence 
of CAAs in patients of Asian, Caucasian, and African ethnicity was 
10.3, 6.9, and 1.2%, respectively (10). In addition to that, a study 
carried out in India reported a large 10–12% incidence of CAA, 
further highlighting the possible genetic and/or environmental 
susceptibility to CAAs (11).
The incidence of CAA is higher in men than in women, 2.2 
versus 0.5%, respectively (6, 12). Results from 5,000 angiograms 
attained from a single institution in the United Kingdom showed 
that 70 patients found to have coronary ectasia and 54 had signifi-
cant atherosclerotic coronary artery disease (ACAD), and there 
was a significant gender difference in the incidence of coronary 
dilatations, with 0.5% of females and 2.2% of males with ACAD 
having concomitant coronary artery ectasia (3). Furthermore, 
although CAAs can be seen at any age, those related to athero-
sclerosis usually appear later in life compared to congenital CAAs 
or those with an underlying inflammatory nature (13).
Anatomical Distribution
The right coronary artery is the most commonly affected, and it is 
involved in 40–70% of CAAs. The left circumflex (23.4%) or the 
left anterior descending artery (32.3%) follows depending on the 
study (14–18). Involvement of three coronary vessels or the left 
main is a much rarer occurrence (3.5%) (4, 19). Atherosclerotic 
or inflammatory coronary aneurysms are usually multiple and 
involve more than one coronary artery. In contrast, congenital, 
traumatic, or dissecting aneurysms typically involve a single 
artery (20).
PATHOGeNeSiS AND eTiOLOGY
The pathophysiological mechanisms behind CAAs remain con-
troversial. While the underlying pathological processes vary with 
each etiology, they appear to contribute to a unifying mechanism 
of inherent vessel wall weakening and subsequent dilatation (21).
CAA and Coronary Artery Disease
The most common cause of CAAs is atherosclerosis, which has 
been linked to 50% of CAAs diagnosed in adults (22). In a large 
angiographic series, the Coronary Artery Surgery Study (CASS) 
registry (5, 23), investigators reported a prevalence of 4.9% (24), 
which exceeded the rates of CAAs in many other angiographic 
studies (0.37–2.53%) (3). As a part of the CASS registry, succes-
sive angiograms from over 20,000 patients were performed and 
analyzed (12). When 1,000 patients with aneurysms and con-
comitant coronary artery disease were compared with patients 
with coronary artery stenoses alone (no aneurysms), they were 
more likely to be male, to have suffered a myocardial infarction 
in the past, and to have a three-vessel atherosclerotic disease. 
Closer analysis of 978 patients with CAAs revealed that 957 of 
them had concomitant coronary artery stenosis. Similar results 
were observed in a retrospective study from Greece, where 5.3% 
(203) of 3,900 patient angiograms analyzed were found to have 
coronary aneurysmal disease; of these 203 patients, 173 had 
associated significant ACAD (25). Both these studies revealed 
no significant difference in the incidence of risk factors such as 
hyperlipidemia, hypertension, diabetes, peripheral vascular dis-
ease, myocardial infarction, smoking, or the presence of a family 
history of CAD. While the increased association between CAAs 
and coronary artery disease could be predictable and unsurpris-
ing across a population who are more likely to receive a diagnostic 
angiogram, the histopathological features of coronary aneurysms 
further support the pathophysiological link between these two 
diseases. Histological examination of atherosclerotic CAAs 
revealed hyalinization and lipid deposition leading to disturbance 
of the intimal and medial layers of the vessel wall and destruction 
of the muscular elastic components (20, 26–31). Further reports 
highlighted the presence of focal areas of calcification and fibrosis 
as well as large cholesterol crystals. Such features weaken the 
vessel wall and decrease its elasticity, ultimately reducing the 
vessel’s tolerance to intraluminal pressures of blood flow, thus 
predisposing it to subsequent dilatation and aneurysm forma-
tion. Long-term transmural inflammation, which is characteristic 
of atherosclerotic disease, further contributes to this process of 
vessel wall weakening (26–32). Additional literature speculates 
that the chronic overstimulation of the vasodilator nitric oxide 
and the local mechanical stresses from stenoses may contribute 
to the weakening of the medial wall of the coronary artery (19).
Genetic Contribution in ACAD-Associated 
CAAs
In support of the predisposition of CAAs in patients with 
coronary artery disease, several genome-wide association 
studies (GWAS) have discovered the association of variants on 
chromosome 9p21.3 with CAD, and this locus was also associ-
ated with an increased risk of various other diseases including 
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abdominal aortic and intracranial aneurysms. The 9p21.3 risk 
allele has been linked to an altered proliferative phenotype that 
promotes adverse vascular remodeling (33–35). Given the similar 
pathogenesis of CAAs with that of larger vessel, further studies 
are essential to quantify the extent of this potential overlap in the 
genetic predispositions to both atherosclerotic and aneurysmal 
disease. Moreover, further investigations to clarify the extent 
to which genetic polymorphisms contribute to the underlying 
pathophysiology of CAAs are essential in addressing whether 
the identification of patients with CAD at a significant risk of 
concomitant CAA will be possible. While the impact of CAAs 
on patient’s survival with coronary artery disease remains under 
debate, CAA sufferers generally carry a worse prognosis than the 
general population (4, 22), thus methods of risk stratification may 
add valuable clinical information.
CAA and Percutaneous Coronary 
interventions
Ever since the dawn of the interventional era, there has been a 
growing concern about the occurrence of CAAs following the 
treatment of ACAD with PCI, including balloon angioplasty, 
stent implantation (36–39), and in particularly, the use of drug-
eluting stents (DESs) (8, 40, 41).
CAA and Stent implantation
Ahn et al. assessed the occurrence of DES-associated CAAs in 
3,616 consecutive patients (a total of 4,419 lesions) who under-
went follow-up angiography after DES implantation. Thirty-four 
CAAs (0.76% per lesion) in 29 patients (0.8% per patient) were 
detected at follow-up at a mean number of 414 ± 213 days follow-
ing DES implantation (40). Present literature demonstrates that 
the incidence of CAAs associated with stent implantation ranges 
from 1.25 to 3.9% (8, 36); however, this is not representative of 
the true occurrence due to the lack of overall data and the specific 
time in which CAAs develop after DES implantation, which is 
affected by various parameters such as the time of angiographic 
investigation following stent implantation as well as the vary-
ing definitions of CAA used and different inclusion criteria for 
further investigations after PCIs. Several mechanisms have been 
proposed to explain the formation of stent-related CAAs, includ-
ing the formation of a coronary dissection and last stent malap-
position (42). The use of oversized, high-pressure balloons during 
PCI can cause dissection of the vessel. It has also been shown that 
the development of CAAs is related to the use of bailout stenting 
after a coronary dissection due to PTCA (43).
While the mechanical factors, mentioned above, drive the 
formation of aneurysms following bare metal stents, DESs carry 
additional features that contribute to the weakening of a coronary 
vessel (44). First, DESs are primed with various cytotoxic antireste-
nosis drugs, which are known to suppress smooth muscle and 
endothelial cell proliferation, thus preventing restenosis (44–46). 
However, this antiproliferative nature of DES has been shown to 
increase the risk of CAAs via mechanisms of delayed neointimal 
healing and reendotheliazation (44, 45, 47). Studies examining 
the actions of drugs in DESs have demonstrated reduced neoin-
timal formation, accompanied with persistent fibrin deposition, 
macrophage infiltration, and an overall decrease in the number 
of smooth muscle cells at both 28 and 180  days following the 
implantation of DES in rabbit iliac and porcine coronary arteries 
(44, 48–52). Second, a significant vascular inflammatory response 
to DES resulting in increased eosinophilic/heterophilic infiltra-
tion into the vessel wall has been observed (53–55). The likely 
explanation for these findings describes a local hypersensitivity 
reaction to the polymer carrying the drug in the DES. Overall, 
hypersensitivity reactions and local cytotoxic effects of drugs 
contribute to the disruption and weakening of all three layers of 
the arterial wall, leading to their expansion and predisposing the 
vessel to aneurysmal disease (44).
In their study, Alfonso et al. analyzed 1,197 patients whom had 
undergone late angiographic evaluation after DES implantation. 
CAAs were found to have developed in 15 patients (1.25%, 95% 
CI: 0.58–1.93); the average time from DES implantation to CAA 
formation was found to be 313 ± 194 days. The 1-year event-free 
survival was 49 ± 14% and was found to be related to the size of the 
CAA. The clinical presentation of the CAAs varied from an acute 
myocardial infarction (in two patients), unstable angina (in four 
patients) to remaining clinically silent in nine patients. This study 
showed that, although DES-related aneurysms are rare, they can 
carry a potentially fatal outcome for patients; one of the patients 
who was asymptomatic on CAA diagnosis died a year later due to 
a CAA-related myocardial infarction (8). Additional studies are 
required to determine the implications of DES-associated CAAs 
and raise this as a potentially rare but fatal complication among 
interventionists. Larger cohort studies are needed to reflect the 
actual burden of CAAs as a complication of DES and further the 
understanding of the long-term safety of DES.
Bioabsorbable vascular scaffolds (BVS) are also emerging 
materials in PCI (56–63). Various processes can drive the dilata-
tion of the vessel wall, after BVS, and these include meticulous 
lesion preparation, gradual scaffold degradation, subsequent 
scaffold strut discontinuity, and consequential outward displace-
ment of the scaffold, causing CAA formation. Further studies 
are warranted to quantify the true incidence and understand the 
underlying pathophysiological mechanism of CAA after BVS 
implantation, as well as with all types of stents, to address the 
challenges of managing such complications (56).
vasculitis
Kawasaki Disease
Kawasaki disease is the most common cause of CAAs in child-
hood and is the second most common cause in adults. KD is an 
acute inflammatory syndrome that may result in acute vasculitis 
of the coronary arteries and subsequent coronary artery dilata-
tion and aneurysm formation; CAAs occur in around 10–15% of 
patients during the acute phase of the disease (64–66).
Inflammation in KD-Associated CAAs
Inflamed tissues in acute KD show infiltration of the arterial 
wall by mononuclear cells, lymphocytes, and macrophages; 
destruction of the internal elastic lamina; necrosis of the smooth 
muscle cells; myointimal proliferation; and subsequent dilations 
or aneurysms of the coronary arteries (65–68). The inflammatory 
cytokine TNF-alpha has been linked to the pathogenesis of CAA 
in KD patients, further supporting the role of inflammation in 
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the development of CAAs. Rapid production of TNF-alpha in the 
peripheral immune system after disease induction in a murine 
model of KD has been shown to localize an immune response to 
the coronary arteries. In addition to that, the level of TNF-alpha 
remained elevated and was linked to the inflammatory process 
and breakdown of elastin that contributed to CAA formation. 
Moreover, pharmacological blockage of TNF-alpha effector 
mechanisms by using etanercept in these murine models was 
shown to eliminate these processes (69). An increased expres-
sion of soluble adhesion molecules in the sera of patients with 
coronary artery ectasias (CAEs) such as vascular cell adhesion 
molecule-1 and intercellular adhesion molecule-1 on the vascular 
endothelium, which play a role in the migration and adherence 
of immune cells (leukocytes) to the coronary arteries, further 
elucidates the inflammatory process’s role in the formation of 
CAA (70).
Genetic Contribution in KD-Associated CAAs
Several GWAS have contributed to the recent identification of 
various gene loci, which can help identify KD patients who are 
at an increased risk of developing CAAs, as well as recognize 
the extent of their vasculitis, to help initiate early diagnosis 
and robust treatment (67, 71–73). For example, Lin and col-
leagues investigated 64 patients with extremely large CAAs 
(diameter >8 mm) and compared them to 70 KD patients without 
CAAs; they revealed an association between the genetic variant 
rs2833195 in the intron of the TIAM1 gene, with the develop-
ment and severity of CAA in KD. They postulated that the TIAM1 
protein may play a role in chemokine-induced T cell migration 
and infiltration of lymphocytes into the vascular wall during the 
acute vasculitis stage of KD (71, 74). The genetic polymorphisms 
identified so far increase the risk of CAAs in KD patients by small 
amounts; therefore, to appreciate the extent of these and further 
undiscovered genetic susceptibilities, future studies are required 
to define the exact molecular mechanisms of CAA.
Matrix Metalloproteinase (MMP) Activity in 
KD-Associated CAAs
Histopathologic samples reveal the destruction of coronary 
artery walls with diffuse vasculitis, suggesting the involvement 
of MMPs in the formation of CAAs. MMPs are enzymes that can 
degrade the connective tissue proteins, leading to a weakened 
vascular wall (68, 75). MMP expression is regulated by transcrip-
tion through a prostaglandin E2–cAMP pathway; inflammatory 
cytokines can stimulate this pathway resulting in an imbalance in 
the levels of MMPs. Tissue-specific inhibitors of MMPs (TIMP-1, 
TIMP-2, TIMP-3, and TIMP-4) are secreted by smooth muscle 
cells and regulate the activity of MMPs. Aneurysmal vessels have 
demonstrated an increased level of MMP-2, MMP-3, MMP-9, and 
MMP-12 and a reduced level of TIMPs; this proteolytic imbal-
ance is thought to drive the degradation of vessel wall matrix and 
lead to CAAs (69, 70, 76). A study by Matsuyama et al. shows 
that the serum levels of MMP-3 and TIMP-1 are significantly 
higher in untreated KD patients than in a healthy control group 
of children (77). Moreover, some evidence highlights the role 
that genetic factors, particularly the variation in MMP-9 gene 
polymorphisms, play in the formation of aneurysms in KD (78). 
HLA-E and MMP-3 gene disruption, as well as insertion/deletion 
polymorphisms of the angiotensin-converting enzyme (ACE DD 
genotype), SRC-1 and GRIN3A genes are further possible genetic 
factors that have been linked to vessel wall weakening and the 
induction of coronary artery ectasias (72, 73, 79–82).
Other Vasculitic Disorders
Takayasu arteritis (TA) is a primary systemic vasculitis and 
involves the large cardiac vessels, mainly the aorta and its branches; 
less than 10% of patients with TA have CAAs (83). There are three 
main types of lesions seen in TA: stenosis or occlusion of the 
coronary ostia, diffuse or focal coronary arteritis, and coronary 
aneurysm (84). Systemic lupus erythematosus also commonly 
causes arteritis. Polyarteritis nodosa and rheumatoid arthritis are 
other vasculitic diseases that may lead CAA (4, 12, 22).
Connective Tissue Disorders
Hereditary connective tissue disorders like Marfan syndrome and 
Ehlers–Danlos disease can also result in CAAs. Marfan syndrome 
is known to be associated with mutations in the fibrillin 1 (FBN1) 
gene (85). Fibrillin forms an essential element of the microfibrils 
that surround the elastin fibers, for maintaining vessel wall integ-
rity (86). The FBN1 gene is homologous with the family of latent 
transforming growth factor-beta (TGF-b)-binding proteins, 
which maintains TGF-b in an inactive complex. Mutations of this 
gene may result in the overactivity of TGF-b and via mechanisms 
of cystic medial necrosis contribute to the formation of CAAs 
(30, 87). Mutations of the TGF-b receptor have been found to 
be associated with arterial aneurysms (88), and cystic medial 
necrosis has been commonly seen in aortic aneurysms in patients 
without Marfan syndrome (89), further supporting the overactiv-
ity of TGF-b as a driver of CAA formation.
Neurofibromatosis (NF) is a congenital hereditary disease 
with generalized neuroectodermal and mesodermal dysplasia 
that affects the skin and multiple systems such as the nervous, 
skeletal and vascular system. There have been a few rare docu-
mented NF cases who suffered a myocardial infarction because 
of thromboembolism (90–92).
infections and Drugs Use
Bacterial, mycobacterial, fungal, syphilitic, Lyme, septic emboli, 
mycotic aneurysm, and HIV infections are also different CAA 
etiologies. The direct invasion of pathogens into the vessel wall or 
immune complex deposition are also known drivers of the CAAs 
in mycotic lesions (93). Some investigators have reported that 
mycotic CAAs after DES implantation are also possible (94). Use 
of drugs such as cocaine, protease inhibitors, amphetamines is 
additionally responsible for CAAs (22, 95). The potential mecha-
nism of CAA formation among cocaine users may be from severe 
hypertension episodes and the direct endothelial damage caused 
by vasoconstriction (96).
Other Causes of CAAs
Congenital CAA is another etiology of CAAs, which accounts 
for 20–30% of all coronary aneurysms; however, the formation of 
congenital CAAs remains poorly understood (97).
Fibromuscular dysplasia (FMD), a non-atherosclerotic and 
non-inflammatory vascular disease, commonly associated with 
FiGURe 1 | Acute coronary syndrome and coronary artery aneurysms. A patient presented with acute coronary aneurysm. (A,B) Coronary angiography 
revealed an aneurysmal dilatation of the ostia of the left anterior descending (LAD) artery and left circumflex artery, with a thrombus image (arrow heads) in the LAD 
artery along with a significant stenosis in the proximal part. Control angiogram failed to show any reduction in the thrombus after 48 h of tirofiban infusion, and the 
patient was referred to the surgery. (C) Aneurysmal dilatation can also be seen in computed tomography images.
FiGURe 2 | A large aneurysm in left anterior descending artery in a 17-year-old patient with neurofibromatosis causing acute coronary syndrome. 
Coronary angiograms with (A) and without (B,C) thrombus image in the aneurysm after anticoagulation. However, this patient was referred to surgery to prevent 
future complications [with permission from the report by Evrengul et al. (92)].
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lesions of the internal carotid and renal arteries, has also been 
described in the coronary arteries (98). For the first time, a CAA 
was reported as a complication of FMD of the intimal, medial, 
adventitial, and periarterial layers (99). This phenomenon could 
further the understanding of the underlying mechanisms of 
congenital CAAs.
CLiNiCAL PReSeNTATiON
In most cases, CAAs are asymptomatic, and when symptomatic, 
the clinical manifestations vary and are typically reliant on the 
underlying cause. Most often, the clinical manifestations of CAAs 
are like those seen in coronary artery disease (3, 8, 100). A fre-
quent finding is the presence of thrombi within the aneurysm. 
The slow flow of blood on the irregular internal surface of the 
aneurysm wall predisposes the formation of thrombi with sub-
sequent embolization, resulting in angina pectoris (Figures  1  
and 2), dyspnea, myocardial ischemia, and/or infarction and 
sudden death (26, 100–102). Angina can also be related to the 
associated atherosclerosis or the sluggish flow caused by the 
aneurysm itself. In some instances, a murmur can be auscultated 
(16, 103, 104). CAAs have also been reported in association 
with an abdominal aortic aneurysm or hypertension. Rupture 
of the aneurysm is a rare occurrence, nonetheless, a potentially 
catastrophic complication of a CAA. Patients with giant CAAs 
can present in a variety of ways, such as with superior vena cava 
syndrome or with a mediastinal mass, which can often be misdi-
agnosed as a cardiac tumor (16, 21, 104, 105). Large aneurysms 
are a diagnostic challenge (105); the differential diagnoses for 
these include cysts and other masses (100). The variation in the 
presentation of CAAs highlights the importance of utilizing a 
variety of diagnostic approaches.
DiAGNOSiS
Coronary artery aneurysms are diagnosed using various imaging 
techniques, and the ideal methods should evaluate the distribution, 
maximal diameter, presence or absence of intraluminal thrombi, 
and the number and extension of aneurysms and associated 
complications, such as a myocardial infarction. Since most of the 
patients with CAAs remain asymptomatic, aneurysms are mostly 
incidentally found during diagnostic coronary angiography (4). 
Although coronary angiography, incorporated with intravascular 
ultrasound (IVUS), remains the conventional method for the 
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assessment of the coronary anatomy and identification of CAAs, 
the limitations of this technique have highlighted the use of other 
diagnostic approaches in the context of CAAs. Furthermore, 
CAAs may also be detected by non-invasive tools including 
echocardiography, CT, and MR imaging (60, 102).
Coronary Angiography
Coronary angiography provides important information about 
the size, shape, location, and frequency of aneurysms, as well as 
the degree of coronary artery atherosclerosis (2, 106, 107). As well 
as evaluating any coronary artery stenoses, coronary angiography 
is also able to detect thrombotic occlusions and determine the 
extent of collateral artery formation. Prior to referring a patient 
for invasive angiography, it is important to consider the benefits 
and risks of the procedure, particularly in younger patients with 
KD. While coronary angiography may not provide further infor-
mation in patients with mild ectasia or small fusiform aneurysms, 
it can play a larger role in more complex coronary lesions. Also, 
conventional angiography is limited to a “luminogram” and does 
not reflect information about the vessel wall, and this could lead to 
the underestimation of the actual size of aneurysm or even over-
look a CAA that may be occluded by a large thrombus or a plaque. 
Coronary angiography is also limited in its ability to differentiate 
between a true aneurysm and a pseudoaneurysm (108–110).
intravascular Ultrasound
Intravascular ultrasound can be incorporated in the invasive 
angiographic evaluation of CAAs, and treatment of CAAs can be 
initiated during the same procedure (20). IVUS has become the 
“gold standard” for providing critical anatomical information to 
address the diagnostic limitations of evaluating coronary aneu-
rysms during angiography (108). Intravascular ultrasonography 
provides transmural images of the coronary arteries, allowing for 
information on the arterial wall structure and luminal composi-
tion to be derived (109, 110). This is important for the differen-
tiation between the different types of aneurysms, which vary in 
prognosis. Pseudoaneurysms are characterized by a loss in the 
vessel wall integrity, resulting in a highly rupture-prone adventitia 
and perivascular tissue; most perforation-related enlargements 
are pseudoaneurysms. On the other hand, most postcoronary 
intervention aneurysms are true aneurysms that follow a healed 
dissection (109). One study used intravascular ultrasound to 
assess coronary artery aneuryms diagnosed by angiography in 
77 patients. Only a third of angiographically confirmed CAAs 
were true or pseudoaneurysms, 27 and 4% respectively. IVUS 
could reveal that most of the remainder of these aneurysms, 
16%, in fact, had the morphology of complex plaques or were 
just normal segments adjacent to stenotic regions, 53% (110). 
Moreover, IVUS is also useful for clarifying the relationship of a 
coronary aneurysm with a previously implanted stent, and this is 
important given the recent association of CAAs with percutane-
ous coronary interventions. Aneurysms can develop outside the 
stent struts when the stent has been implanted for the treatment of 
a coronary dissection (111). IVUS can also be used as an adjunct 
during cardiac catheterization to detect structural or functional 
changes in the coronary artery wall (110). IVUS on the angio-
graphically documented regressed CAAs demonstrates unusual 
thickening of the intima-media complex as well as a reduced vaso-
active response to vasodilators (112–114). The long-term clinical 
implications of these anatomical and functional changes are cur-
rently unknown and may be underline fundamental features in 
the natural history of CAAs (111). IVUS can also be used during 
the treatment of CAAs; it proves to be an invaluable tool in guid-
ing the adequate coverage of aneurysms (108).
CT Angiography
Most recently, multidetector-row computed tomography (MDCT) 
technology has led to an increased interest for the use of non-
invasive coronary angiography. MDCT has been utilized in the 
context of CAAs, despite its ill-defined role in the management of 
patients with cardiovascular symptoms (115). In fact, the advent 
of MDCT has increased the incidental finding of coronary aneu-
rysms and ectasia, which were previously a rare finding on coro-
nary angiography (3). CT data acquisitions can be reconstructed 
to provide information regarding the nature of the dilatation 
in the coronary vessel, such as the maximum diameter, shape, 
morphology, and presence of any concomitant stenosis, plaque 
composition, and its location in relation to the surrounding 
vasculature (4). The limitations of coronary angiography in the 
detection of coronary aneurysms (i.e., underestimation of CAA 
size in the presence of intraluminal thrombi) have fueled investi-
gators to assess the prospective role of CTCA in the diagnosis of 
CAA. Recently, Forte et al. retrospectively analyzed 390 consecu-
tive CTCAs performed from 2007 to 2015 for suspected CAD or 
follow-up after myocardial ischemia; they divided patients into 
two groups, those with and those without CAAs. CTCA could 
identify aneurysmal thrombus in five patients (55.5%), and a 
significant difference in the diameter of the coronary vessels was 
found between the two groups of patients (116).
CTCA provides a fast three-dimensional evaluation that 
helps to provide an easy understanding of complex anatomic 
structures, such as those seen in ectasia associated with coronary 
fistulas, as well as allow for the analysis of the lumen composition 
and the vessel wall. While coronary angiography allows for both 
diagnosis and treatment of CAAs, CTCA could be used for the 
follow-up of patients with suspected or treated CAAs.
Nonetheless, this method requires the exposure to radiation 
and the use of iodinated contrast media; such issues should be 
considered when evaluating young patients who require follow-
up investigations, as well as patients with renal failure. To address 
this, prospective electrocardiographically gated scans and dose 
modulation techniques have been devised to reduce the radiation 
(117, 118). Nonetheless, there are limited data published from 
large series studies regarding the coronary CT angiography in the 
diagnosis of CAAs (4). Further studies are required to compare 
the sensitivity and specificity of CTCA in the detection of CAAs 
compared to that of the current “gold standard” to help postulate 
its prospective role in the diagnosis of CAAs.
echocardiography
Other non-invasive methods, useful for the diagnosis of CAAs, 
include transthoracic echocardiography and transesophageal 
echocardiography (107). The non-invasive nature of echocar-
diography, as well as its high sensitivity and specificity for the 
FiGURe 3 | A patient with coronary aneurysm due to Kawasaki disease. (A) Computed tomography angiography showed a large aneurysm (maximum 
diameter 9 mm, extending for more than 35 mm) of the proximal left anterior descending (LAD) artery with calcific degeneration, large filling defect with thrombus 
and severe lumen narrowing. (B) Coronary angiography confirmed a 70% stenosis of the LAD artery with an aneurysm immediately distal to the ostium (maximum 
diameter 9.2 mm × 7.8 mm). (C) Final angiography demonstrating exclusion of the aneurysm using a covered stent [with permission from the report by Di Mario 
et al. (133)].
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detection of abnormalities in the proximal LMCA and RCA, 
makes it an ideal imaging modality for the assessment of the 
cardiac sequel of KD in children. Echocardiography allows for 
the quantitative assessment of the internal vessel diameters, 
providing information on the location of the aneurysms and the 
presence or absence of intraluminal thrombi. Depending on the 
relation of the axial and lateral diameters of the coronary ves-
sels to each other, one can identify the nature of the aneurysm. 
Echocardiography is also a useful non-invasive method to 
guide the long-term follow-up of these patients into adulthood, 
alongside coronary angiography; it has also been suggested that 
the decision to perform angiography may be guided by echocar-
diographic imaging of coronary arteries (111).
Coronary MR Angiography (MRA)
As previously mentioned, echocardiographic evaluation becomes 
increasingly limited as children grow up (107); here, coronary 
MRA is a useful alternative. MRA may also be a useful substitute 
in patients for whom the use of other non-invasive modalities 
may be contraindicated. MRA may describe CAAs in proximal 
coronary artery segments and feedback information regarding 
flow rate and character (119, 120). A recent series on KD patients 
demonstrated the ability of MRA in effectively diagnosing all 
CAAs, occlusions, and stenoses, which were found on coronary 
angiography (121). Current literature supports the ability of MRA 
to investigate large proximal segments of the coronary vascula-
ture; however, the resolution of MRA is reduced when it comes 
to imaging the smaller distal segments. Therefore, additional 
studies in patients with KD and CAAs are needed to establish the 
reliability of MRA in the diagnosis of CAAs and stenoses in distal 
arterial segments (122).
TReATMeNT
There is no consensus on the optimal management of CAAs, and 
the treatment options for CAAs consist of surgical, percutaneous, 
and medical approaches. Since the natural history and prognosis 
are related to multiple factors, the decisions around treatment 
should be tailored to each patient and should consider many 
aspects such as the clinical presentation, etiology, aneurysm size, 
location and its expansion by time, association with infections, 
and the presence and extent of any coexisting atherosclerosis 
(12, 19, 76, 123, 124).
Medical Treatment
Patients with atherosclerosis should receive guideline-directed 
medical therapy to modify their coronary artery disease risk fac-
tors. The possible link between the inflammatory cytokines and 
MMPs with CAAs may also indicate a role for statins and inhibi-
tion of the renin–angiotensin system (30); however, there are no 
studies, to date, supporting these hypotheses. If thrombosis and/
or embolism is a concern, the long-term use of antiplatelet and 
anticoagulant therapy should be considered (25).
Intravenous immunoglobulin (IVIG) therapy is used in 
patients with Kawasaki disease for the treatment of coronary 
artery aneurysms. The early initiation of treatment and a smaller 
sized coronary artery aneurysm at diagnosis, have both been 
associated with a higher rate of CAA regression as well as a 
lower incidence of major adverse-coronary events (125–127). 
Although the use of IVIG in KD patients is beyond the scope of 
this review, it is important to mention these recent findings that 
have highlighted the prognostic benefits of the early recognition 
and treatment of KD-associated CAAs and emphasized the need 
for further studies to comprehend the identifiable risk factors and 
predispositions (such as the genetic susceptibility loci previously 
discussed) to developing CAAs.
Percutaneous intervention
In some cases, a decision can be made to exclude the aneurysm 
to prevent future complications. During decision making, it is 
important to weigh both the immediate and the long-term risks 
that surround percutaneous interventions or surgery versus 
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the complications that can occur on prolonged antithrombotic 
medication, such as bleeding. In the instance where percutaneous 
exclusion has been decided upon, covered stents are recom-
mended, in those with the suitable anatomy (Figure 3) (128, 129). 
However, concerns around the use of covered stents still exist and 
should also be considered, and these include a reduced deliver-
ability, the risk of restenosis and thrombosis, and occlusion of side 
branches (130). In a previous case series of seven CAA patients, 
Briguori et al. treated them with (PTFE)-covered stents; at 35 ± 8 
months of clinical follow-up, six patients were found to be symp-
tom free. During the angiographic follow-up at 10 ± 6 months, 
restenosis occurred in only one patient (131). In an analysis of 
the previous cases in 2005, authors reported that only 5 of the 
24 patients who received stents were found to have restenosis 
on follow-up angiography; these patients had larger aneurysms 
(>10 mm in diameter) (132). These results were compared with 
a preceding study that reviewed patients undergoing surgical 
treatment for CAA, and they recommended the use of covered 
stents for small-sized CAAs and surgery for large aneurysms 
(greater than 10 mm); however, this study was relatively small, 
lacked controls, and had heterogeneous data.
Another percutaneous option in the management of wide-
necked aneurysms is coil insertion (134, 135); however, experience 
is needed to perform these interventions. Also, coil herniation can 
lead to the occlusion of the parent vessel; therefore, stent-assisted 
techniques are preferred. Another pitfall is the risk of aneurysm 
rupture during the manipulation of the microcatheter, coils, or 
wires (134).
Surgery
Finally, surgery is an alternative for patients whom cannot 
be treated percutaneously. It is also indicated in patients with 
obstructive coronary artery disease or in individuals with large 
saccular aneurysms at a high risk of rupturing (107). Several 
FiGURe 4 | A 70-year-old male presented with angina on exertion. Three years prior to this presentation, they had an abdominal aortic aneurysm repair. 
(A,B) Coronary angiogram revealed coronary artery disease and an aneurysm in the left anterior descending artery. The patient was referred to surgery, because  
of the risk of occlusion of the significant side branches, if a stent was to be used. (C,D) Coronary aneurysm was surgically excluded with a linear repair (images 
courtesy of Yalin Tolga Yaylali and Bilgin Emrecan).
9
Abou Sherif et al. Coronary Artery Aneurysms: A Review
Frontiers in Cardiovascular Medicine | www.frontiersin.org May 2017 | Volume 4 | Article 24
ReFeReNCeS
1. Markis JE, Joffe CD, Cohn PF, Feen DJ, Herman MV, Gorlin R. Clinical 
significance of coronary arterial ectasia. Am J Cardiol (1976) 37(2):217–22. 
doi:10.1016/0002-9149(76)90315-5 
2. Topaz O, Rutherford MS, Mackey-Bojack S, Prinz AW, Katta S, Salter D, 
et al. Giant aneurysms of coronary arteries and saphenous vein grafts: angio-
graphic findings and histopathological correlates. Cardiovasc Pathol (2005) 
14:298–302. doi:10.1016/j.carpath.2005.08.007 
3. Hartnell GG, Parnell BM, Pridie RB. Coronary artery ectasia: its prevalence 
and clinical significance in 4993 patients. Br Heart J (1985) 54:392–5. 
doi:10.1136/hrt.54.4.392 
4. Packard M, Wechsler HF. Aneurysms of coronary arteries. Arch Intern Med 
(1929) 43:1–14. doi:10.1001/archinte.1929.00130240004001 
5. Robertson T, Fisher L. Prognostic significance of coronary artery aneurysm 
and ectasia in the Coronary Artery Surgery Study (CASS) registry. Prog Clin 
Biol Res (1987) 250:325–39. 
6. Tunick PA, Slater J, Pasternack P, Kronzon I. Coronary artery aneurysms: a 
transesophageal echocardiographic study. Am Heart J (1989) 118(1):176–9. 
doi:10.1016/0002-8703(89)90091-4 
7. Lanjewar CP, Sharma A, Sheth T. IVUS-guided management of late stent 
malaposition with peri-stent restenosis with coronary artery aneurysm fol-
lowing drug-eluting stent implantation (paxlitaxel-eluting stent). J Invasive 
Cardiol (2009) 21:E87–90. 
8. Alfonso F, Pérez-Vizcayno MJ, Ruiz M, Suárez A, Cazares M, Hernández R, 
et  al. Coronary aneurysms after drug-eluting stent implantation: clinical, 
angiographic, and intravascular ultrasound findings. J Am Coll Cardiol 
(2009) 53:2053–60. doi:10.1016/j.jacc.2009.01.069 
9. Antoniadis AP, Chatzizisis YS, Giannoglou GD. Pathogenetic mechanisms 
of coronary ectasia. Int J Cardiol (2008) 130(3):335–43. doi:10.1016/j.
ijcard.2008.05.071 
10. Porcella AR, Sable CA, Patel KM, Martin GR, Singh N. The epidemiology of 
Kawasaki disease in an urban hospital: does African American race protect 
against coronary artery aneurysms? Pediatr Cardiol (2005) 26:775–81. 
doi:10.1007/s00246-005-0916-5 
11. Sharma SN, Kaul U, Sharma S, Wasir HS, Manchanda SC, Bahl VK, et al. 
Coronary arteriographic profile in young and old Indian patients with 
ischemic heart disease: a comparative study. Indian Heart J (1990) 42:365–9. 
12. Swaye PS, Fisher LD, Litwin P, Vignola PA, Judkins MP, Kemp HG, et  al. 
Aneurysmal coronary artery disease. Circulation (1983) 67(1):134–8. 
doi:10.1161/01.CIR.67.1.134 
13. Doustkami H, Maleki N, Tavosi Z. Left main coronary artery aneurysm. 
J Tehran Heart Cent (2016) 11(1):41–5. 
14. Villines TC, Avedissian LS, Elgin EE. Diffuse non-atherosclerotic coronary 
aneurysms. Cardiol Rev (2005) 13:309–11. doi:10.1097/01.crd.0000159579. 
77038.dc 
15. Vranckx P, Pirot L, Benit E. Giant left main coronary artery aneurysm in asso-
ciation with severe atherosclerotic coronary disease. Cathet Cardiovasc Diagn 
(1997) 42(1):54–7. doi:10.1002/(SICI)1097-0304(199709)42:1<54::AID- 
CCD16>3.0.CO;2-M 
16. Jha NK, Ouda HZ, Khan JA, Eising GP, Augustin N. Giant right coronary 
artery aneurysm – case report and literature review. J Cardiothorac Surg 
(2009) 4:18. doi:10.1186/1749-8090-4-18 
17. Nazareth J, Weinberg L, Fernandes J, Peyton P, Seevanayagam S. Giant right 
coronary artery aneurysm presenting with non-ST elevation myocardial 
infarction and severe mitral regurgitation: a case report. J Med Case Rep 
(2011) 5:442. doi:10.1186/1752-1947-5-442 
18. Manginas A, Cokkinos DV. Coronary artery ectasias: imaging, functional 
assessment and clinical implications. Eur Heart J (2006) 27(9):1026–31. 
doi:10.1093/eurheartj/ehi725 
19. Syed M, Lesch M. Coronary artery aneurysm: a review. Prog Cardiovasc Dis 
(1997) 40(1):77–84. doi:10.1016/S0033-0620(97)80024-2 
20. Mata KM, Fernandes CR, Floriano EM, Martins AP, Rossi MA, Ramos SG. 
Coronary artery aneurysms: an update. In:  Lakshmanadoss  U, editor. Novel 
Strategies in Ischemic Heart Disease. Rijeka, Croatia: InTech (2012). p. 381–404.
21. Crawley P, Mahlow W, Huntsinger D, Afiniwala S, Wortham D. Giant 
coronary artery aneurysms: review and update. Tex Heart Inst J (2014) 
41(6):603–8. doi:10.14503/THIJ-13-3896 
22. Cohen P, O’Gara PT. Coronary artery aneurysms. A review of the natural 
history, pathophysiology, and management. Cardiol Rev (2008) 16(6):301–4. 
doi:10.1097/CRD.0b013e3181852659 
23. Emond M, Mock M, Davis K, Fisher L, Holmes D, Chaitman B, et al. Long-term 
survival of medically treated patients in the Coronary Artery Surgery Study 
(CASS) registry. Circulation (1994) 90(6):2645–57. doi:10.1161/01.CIR.90.6.2645 
24. Principal Investigators of CASS and Their Associates. National heart, lung, 
and blood institute coronary artery surgery study. Circulation (1981) 63 
(Suppl I):Il–81. 
25. Demopoulos VP, Olympios CD, Fakiolas CN, Pissimissis EG, Economides 
NM, Adamopoulou E, et  al. The natural history of aneurysmal coronary 
artery disease. Heart (1997) 78(2):136–41. doi:10.1136/hrt.78.2.136 
26. Alford  WC Jr, Stoney WS, Burrus GR, Frist RA, Thomas  CS Jr. Recognition 
and operative management of patients with arteriosclerotic coronary artery 
aneurysms. Ann Thorac Surg (1976) 22(4):317–21. doi:10.1016/S0003-4975 
(10)64961-2 
27. Robinson FC. Aneurysms of the coronary arteries. Am Heart J (1985) 
109(1):129–35. doi:10.1016/0002-8703(85)90425-9 
procedures can be performed during surgery, and these include 
resection of the aneurysm, proximal and/or distal ligation 
(Figure  4), aneurysmal thrombectomy, and aneurysmectomy 
with or without bypass grafting (128).
CONCLUSiON
In retrospect, while our understanding of CAAs has developed 
over the last few years, a great deal remains unknown. CAAs are 
rare; nonetheless, it can result in fatal outcomes in patients. CAAs 
are most commonly associated with coronary artery disease, and 
there is a growing concern regarding the development of CAAs 
following percutaneous coronary interventions. Several studies 
have postulated the underlying pathophysiology of CAA; how-
ever, the specific mechanisms that drive the formation of CAAs 
remain unclear. Despite the multifactorial nature of CAA, the 
recent discovery of genetic polymorphisms that may increase 
the risk of CAA in patients such as those with KD, in addition 
to the prognostic benefits of the early diagnosis and treatment 
of CAAs, emphasizes the need for further studies to consolidate 
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and subsequent complications. With more widespread use of 
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will improve.
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